


**What is claimed is:**


1. A compound of Formula (I):




or a pharmaceutically acceptable salt thereof, wherein:

$\text{R}^7$  is a peptide;

$\text{R}^8$  is:



Q is:



$\text{R}^1$  and  $\text{R}^3$  together with the carbon atoms to which they are attached form a  $\text{C}_{3-14}$  cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from  $\text{C}_{1-4}$  alkyl, halo, CN,  $\text{NO}_2$ ,  $\text{OR}^{\text{a1}}$ ,  $\text{SR}^{\text{a1}}$ ,  $\text{C(O)R}^{\text{b1}}$ ,  $\text{C(O)NR}^{\text{c1}}\text{R}^{\text{d1}}$ ,  $\text{C(O)OR}^{\text{a1}}$ ,  $\text{OC(O)R}^{\text{b1}}$ ,  $\text{OC(O)NR}^{\text{c1}}\text{R}^{\text{d1}}$ ,  $\text{NR}^{\text{c1}}\text{R}^{\text{d1}}$ ,  $\text{NR}^{\text{c1}}\text{C(O)R}^{\text{b1}}$ ,  $\text{NR}^{\text{c1}}\text{C(O)OR}^{\text{a1}}$ , and  $\text{NR}^{\text{c1}}\text{C(O)NR}^{\text{c1}}\text{R}^{\text{d1}}$ ;

$\text{R}^2$  and  $\text{R}^4$  are each independently selected from H,  $\text{C}_{1-4}$  alkyl,  $\text{C}_{1-4}$  alkenyl,  $\text{C}_{6-10}$  aryl,  $\text{C}_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, halo, CN,  $\text{NO}_2$ ,  $\text{OR}^{\text{a1}}$ ,  $\text{SR}^{\text{a1}}$ ,  $\text{C(O)R}^{\text{b1}}$ ,  $\text{C(O)NR}^{\text{c1}}\text{R}^{\text{d1}}$ ,  $\text{C(O)OR}^{\text{a1}}$ ,  $\text{OC(O)R}^{\text{b1}}$ ,  $\text{OC(O)NR}^{\text{c1}}\text{R}^{\text{d1}}$ ,  $\text{NR}^{\text{c1}}\text{R}^{\text{d1}}$ ,  $\text{NR}^{\text{c1}}\text{C(O)R}^{\text{b1}}$ ,  $\text{NR}^{\text{c1}}\text{C(O)OR}^{\text{a1}}$ , and  $\text{NR}^{\text{c1}}\text{C(O)NR}^{\text{c1}}\text{R}^{\text{d1}}$ , wherein said  $\text{C}_{1-4}$  alkyl,  $\text{C}_{1-4}$  alkenyl,  $\text{C}_{6-10}$

10 aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO<sub>2</sub>, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, and NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>; and

R<sup>a1</sup>, R<sup>b1</sup>, R<sup>c1</sup>, and R<sup>d1</sup> are each independently selected from H, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, OH, CN, NO<sub>2</sub>, and CO<sub>2</sub>CH<sub>3</sub>; wherein said C<sub>1-6</sub> alkyl and C<sub>2-6</sub> alkenyl are each optionally substituted with OH, CN, NO<sub>2</sub>, or CO<sub>2</sub>CH<sub>3</sub>.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>7</sup> is a peptide capable of selectively delivering R<sup>8</sup>Q- across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.0.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>7</sup> is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1);

AEQNPIYWARYADWLFTTPLLALLVDADECG (SEQ ID NO: 2; Pv2);

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3);

Ac-AAEQNPIYWARYADWLFTTPLLALLVDADEGKCG (SEQ ID NO: 4; Pv4); and

AAEQNPIYWARYADWLFTTPLLALLVDADEGTC (SEQ ID No. 5; Pv5);

and wherein R<sup>7</sup> is attached to Q through a cysteine residue of R<sup>7</sup>.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>7</sup> is a peptide comprising at least one of the following sequences:


ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1),

AEQNPIYWARYADWLFTTPLLALLVDADECG (SEQ ID NO: 2; Pv2), and

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3),


and wherein R<sup>7</sup> is attached to Q through a cysteine residue of R<sup>7</sup>.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>7</sup> is a peptide comprising the sequence: ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1).
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>7</sup> is a peptide comprising the sequence: AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2).
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> and R<sup>3</sup> together with the carbon atom to which they are attached form a cyclopentyl, cyclohexyl, cycloheptyl, 1,2,3,4-tetrahydronaphthyl, tetrahydrofuranyl, or tetrahydropyranyl.
8. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> and R<sup>3</sup> together with the carbon atom to which they are attached form a C<sub>3-7</sub> cycloalkyl group.
9. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> and R<sup>3</sup> together with the carbon atom to which they are attached form a cyclohexyl group.
10. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein Q is:



11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R<sup>2</sup> and R<sup>4</sup> are each H.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having Formula (II):



or a pharmaceutically acceptable salt thereof, wherein:

Ring Z is a monocyclic C<sub>5-7</sub> cycloalkyl ring or a monocyclic 5-7 membered heterocycloalkyl ring;

each R<sup>Z</sup> is independently selected from C<sub>1-4</sub> alkyl, halo, CN, NO<sub>2</sub>, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, and NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>;

or two adjacent R<sup>Z</sup> together with the atoms to which they are attached form a fused monocyclic C<sub>5-7</sub> cycloalkyl ring, a fused monocyclic 5-7 membered heterocycloalkyl ring, a fused C<sub>6-10</sub> aryl ring, or a fused 6-10 membered heteroaryl ring, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-4</sub> alkyl, halo, CN, NO<sub>2</sub>, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, and NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>;

R<sup>a1</sup>, R<sup>b1</sup>, R<sup>c1</sup>, and R<sup>d1</sup> are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, OH, CN, and NO<sub>2</sub>; and

n is 0, 1, 2, or 3.

13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R<sup>7</sup> is a peptide comprising the sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R<sup>7</sup> is Pv1, Pv2, Pv3, Pv4, or Pv5.

15. The compound of any one of claims 12-14, or a pharmaceutically acceptable salt thereof, wherein  $R^7$  is attached to the core via a cysteine residue of  $R^7$  wherein one of the sulfur atoms of the disulfide moiety in Formula II is derived from the cysteine residue.
16. The compound of any one of claims 12-15, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a monocyclic  $C_{5-7}$  cycloalkyl ring.
17. The compound of any one of claims 12-15, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a cyclopentyl ring.
18. The compound of any one of claims 12-15, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a cyclohexyl ring.
19. The compound of any one of claims 12-15, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a cycloheptyl ring.
20. The compound of any one of claims 12-15, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a monocyclic 5-7 membered heterocycloalkyl ring.
21. The compound of any one of claims 12-15, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a 5-membered heterocycloalkyl ring.
22. The compound of any one of claims 12-15, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a 6-membered heterocycloalkyl ring.
23. The compound of any one of claims 12-15, or a pharmaceutically acceptable salt thereof, wherein Ring Z is a 7-membered heterocycloalkyl ring.
24. The compound of any one of claims 12-23, or a pharmaceutically acceptable salt thereof, wherein two adjacent  $R^Z$  together with the atoms to which they are attached form a fused

monocyclic C<sub>5-7</sub> cycloalkyl ring, a fused monocyclic 5-7 membered heterocycloalkyl ring, a fused C<sub>6-10</sub> aryl ring, or a fused 6-10 membered heteroaryl ring, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-4</sub> alkyl, halo, CN, NO<sub>2</sub>, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, and NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>.


25. The compound of any one of claims 12-23, or a pharmaceutically acceptable salt thereof, wherein n is 0.



26. The compound of any one of claims 12-23, or a pharmaceutically acceptable salt thereof, wherein n is 1.

27. The compound of any one of claims 12-23, or a pharmaceutically acceptable salt thereof, wherein n is 2.

28. The compound of any one of claims 12-23, or a pharmaceutically acceptable salt thereof, wherein n is 3.


29. The compound of claim 12-15 and 24-25, wherein the compound has Formula (III), Formula (IV), or Formula (V):






or a pharmaceutically acceptable salt thereof.

30. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is selected from:












wherein Pv2 is a peptide comprising the sequence:




AEQNPIYWARYADWLFTTPLLLDLALLVDADECG (SEQ ID NO: 2).




31. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is selected from:
















wherein Pv1 is a peptide comprising the sequence:  
 ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1).

32. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:



wherein Pv1 is a peptide comprising the sequence:  
 ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1).

33. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is:



wherein Pv1 is a peptide comprising the sequence:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1).

34. A pharmaceutical composition that comprises a compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof.

35. Use of a therapeutically effective amount of a compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer in a patient in need thereof.

36. The use of claim 35, wherein the cancer is selected from bladder cancer, bone cancer, glioma, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, epithelial cancer, esophageal cancer, Ewing's sarcoma, pancreatic cancer, gallbladder cancer, gastric cancer, gastrointestinal tumors, head and neck cancer, intestinal cancers, Kaposi's sarcoma, kidney cancer, laryngeal cancer, liver cancer, lung cancer, melanoma, prostate cancer, rectal cancer, renal clear cell carcinoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, and uterine cancer.

37. The use of claim 35, wherein the cancer is selected from breast cancer, colorectal cancer, and gastric cancer.

38. The use of claim 36 or 37, wherein the breast cancer is triple-negative breast cancer.